Syros Pharmaceuticals Inc (SYRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Sales | 9,936 | 14,880 | 23,488 | 15,093 | 1,982 |
| Gross Profit | 9,936 | 14,880 | 23,488 | 15,093 | 1,982 |
| Operating Expenses | 138,924 | 150,753 | 122,908 | 97,390 | 79,723 |
| Operating Income | -128,988 | -135,873 | -99,420 | -82,297 | -77,741 |
| Interest Expense | 5,127 | 4,134 | 3,907 | 1,792 | 72 |
| Other Income | -30,459 | 45,353 | 16,769 | 51 | 2,375 |
| Pre-tax Income | -164,574 | -94,654 | -86,558 | -84,038 | -75,438 |
| Net Income Continuous | -164,574 | -94,654 | -86,558 | -84,038 | -75,438 |
| Net Income | $-164,574 | $-94,654 | $-86,558 | $-84,038 | $-75,438 |
| EPS Basic Total Ops | -5.81 | -7.49 | -13.84 | -18.20 | -18.80 |
| EPS Basic Continuous Ops | -5.81 | -7.49 | -13.84 | -18.25 | -18.76 |
| EPS Diluted Total Ops | -5.81 | -7.49 | -13.84 | -18.20 | -18.80 |
| EPS Diluted Continuous Ops | -5.81 | -7.49 | -13.84 | -18.25 | -18.76 |
| EPS Diluted Before Non-Recurring Items | -4.70 | -9.33 | -14.20 | -18.10 | -18.80 |
| EBITDA(a) | $-126,162 | $-132,475 | $-95,696 | $-78,975 | $-75,019 |